Rein Therapeutics (RNTX) Competitors $1.46 +0.04 (+2.82%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock RNTX vs. MCRB, ACTU, TARA, ONCY, PLX, SKYE, CTOR, BHST, ATOS, and HURAShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Seres Therapeutics (MCRB), Actuate Therapeutics (ACTU), Protara Therapeutics (TARA), Oncolytics Biotech (ONCY), Protalix BioTherapeutics (PLX), Skye Bioscience (SKYE), Citius Oncology (CTOR), BioHarvest Sciences (BHST), Atossa Genetics (ATOS), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Seres Therapeutics Actuate Therapeutics Protara Therapeutics Oncolytics Biotech Protalix BioTherapeutics Skye Bioscience Citius Oncology BioHarvest Sciences Atossa Genetics TuHURA Biosciences Rein Therapeutics (NASDAQ:RNTX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Does the media prefer RNTX or MCRB? In the previous week, Seres Therapeutics had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 3 mentions for Seres Therapeutics and 1 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.89 beat Seres Therapeutics' score of 1.25 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rein Therapeutics Very Positive Seres Therapeutics Positive Which has better valuation & earnings, RNTX or MCRB? Seres Therapeutics has higher revenue and earnings than Rein Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.86-0.51Seres Therapeutics$126.32M1.00$140K-$4.60-3.16 Is RNTX or MCRB more profitable? Rein Therapeutics' return on equity of -86.07% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -86.07% -31.11% Seres Therapeutics N/A -41,084.76%-55.87% Do insiders & institutionals hold more shares of RNTX or MCRB? 90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, RNTX or MCRB? Rein Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Do analysts recommend RNTX or MCRB? Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 407.00%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 SummaryRein Therapeutics and Seres Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.46M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.5121.0428.0720.05Price / SalesN/A284.46448.5799.42Price / Cash3.1742.7636.2258.56Price / Book3.408.378.665.87Net Income-$62.88M-$55.19M$3.25B$258.55M7 Day Performance2.82%5.89%4.20%2.23%1 Month Performance-5.19%17.63%10.82%12.76%1 Year PerformanceN/A5.09%34.70%19.36% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.46+2.8%N/AN/A$31.46MN/A-0.519MCRBSeres Therapeutics3.5046 of 5 stars$14.07-0.1%$73.67+423.6%-48.1%$122.95M$126.32M-3.06330Positive NewsACTUActuate Therapeutics2.3621 of 5 stars$5.76-8.0%$20.50+255.9%N/A$122.82MN/A0.0010News CoverageTARAProtara Therapeutics2.1431 of 5 stars$3.08-1.9%$20.50+565.6%+44.0%$121.15MN/A-1.7930ONCYOncolytics Biotech1.6669 of 5 stars$1.27-3.8%$4.33+241.2%+10.7%$119.74MN/A-4.3830News CoverageUpcoming EarningsPLXProtalix BioTherapeutics2.9429 of 5 stars$1.45-3.3%$15.00+934.5%+34.2%$115.43M$59.76M-11.15200Gap UpSKYESkye Bioscience2.523 of 5 stars$3.89+4.6%$16.60+326.7%-32.7%$115.22MN/A-4.7411News CoverageGap UpCTORCitius Oncology1.6938 of 5 stars$1.53-4.4%$3.00+96.1%N/A$114.48MN/A0.00N/APositive NewsGap UpBHSTBioHarvest SciencesN/A$6.92+0.1%$13.67+97.5%N/A$113.49M$25.19M-13.84N/ANews CoverageATOSAtossa Genetics3.0234 of 5 stars$0.84-3.2%$6.17+632.5%-38.4%$112.31MN/A-4.018News CoveragePositive NewsHURATuHURA Biosciences1.7927 of 5 stars$2.62+3.6%$12.67+383.5%N/A$110.51MN/A0.00N/A Related Companies and Tools Related Companies MCRB Competitors ACTU Competitors TARA Competitors ONCY Competitors PLX Competitors SKYE Competitors CTOR Competitors BHST Competitors ATOS Competitors HURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNTX Stock Alerts